📊 CNSP Key Takeaways
Is CNS Pharmaceuticals, Inc. (CNSP) a Good Investment?
CNS Pharmaceuticals is a severely distressed pre-revenue biotech company with negative operating cash flow of -4.6M, stockholders' equity of only 70.7K, and just 3M in cash against annual burn rates suggesting <1 year runway. The company is financially insolvent on a book value basis with liquidity ratios below 1.0, facing imminent capital depletion absent significant financing or revenue generation.
CNS Pharmaceuticals appears to be a pre-revenue biotech with no operating income, persistent net losses, and deeply negative cash flow, which makes the fundamental profile highly speculative. While the balance sheet is currently clean with substantial cash relative to liabilities, the business lacks revenue support and is consuming cash at a pace that raises ongoing funding and dilution risk. Improvement in diluted EPS does not offset the core issue of an unprofitable, cash-burning operating model.
CNS Pharmaceuticals, Inc. Key Strengths (CNSP)
- Minimal long-term debt burden reduces leverage risk
- EPS loss improvement trend (-7.30 vs prior -9.68) shows cost control
- 3M cash reserve provides short-term liquidity buffer
- Strong near-term liquidity with $9.86M of cash and 5.81x current and quick ratios
- No meaningful long-term debt, limiting balance-sheet leverage risk
- Liabilities are low relative to equity, providing some short-term financial flexibility
CNSP Stock Risks: CNS Pharmaceuticals, Inc. Investment Risks
- Operating cash burn of -4.6M annually against 3M cash reserves indicates <1 year runway
- Stockholders equity of 70.7K indicates near-complete capital depletion
- Current ratio of 0.89x signals inability to cover short-term obligations
- Zero revenue generation with -4.9M net losses unsustainable long-term
- Negative ROE (-6982.6%) and ROA (-106.1%) demonstrate value destruction
- No revenue base and continued operating losses indicate weak business sustainability
- Negative operating cash flow of $10.76M suggests limited cash runway without new financing
- Very weak returns on equity and assets reflect poor capital efficiency and elevated dilution risk
Key Metrics to Watch
- Monthly burn rate and updated cash runway calculations
- Financing announcements or capital raise events
- Clinical trial progress and regulatory milestones for drug candidates
- Quarterly operating cash burn versus cash balance
- Clinical/regulatory progress translating into revenue-generating partnerships or commercialization
CNS Pharmaceuticals, Inc. (CNSP) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
CNSP Profit Margin, ROE & Profitability Analysis
CNSP vs Healthcare Sector: How CNS Pharmaceuticals, Inc. Compares
How CNS Pharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is CNS Pharmaceuticals, Inc. Stock Overvalued? CNSP Valuation Analysis 2026
Based on fundamental analysis, CNS Pharmaceuticals, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
CNS Pharmaceuticals, Inc. Balance Sheet: CNSP Debt, Cash & Liquidity
CNSP Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: CNS Pharmaceuticals, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-466.89 indicates the company is currently unprofitable.
CNSP Revenue Growth, EPS Growth & YoY Performance
CNS Pharmaceuticals, Inc. Dividends, Buybacks & Capital Allocation
CNSP SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for CNS Pharmaceuticals, Inc. (CIK: 0001729427)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CNSP
What is the AI rating for CNSP?
CNS Pharmaceuticals, Inc. (CNSP) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 92% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CNSP's key strengths?
Claude: Minimal long-term debt burden reduces leverage risk. EPS loss improvement trend (-7.30 vs prior -9.68) shows cost control. ChatGPT: Strong near-term liquidity with $9.86M of cash and 5.81x current and quick ratios. No meaningful long-term debt, limiting balance-sheet leverage risk.
What are the risks of investing in CNSP?
Claude: Operating cash burn of -4.6M annually against 3M cash reserves indicates <1 year runway. Stockholders equity of 70.7K indicates near-complete capital depletion. ChatGPT: No revenue base and continued operating losses indicate weak business sustainability. Negative operating cash flow of $10.76M suggests limited cash runway without new financing.
What is CNSP's revenue and growth?
CNS Pharmaceuticals, Inc. reported revenue of N/A.
Does CNSP pay dividends?
CNS Pharmaceuticals, Inc. does not currently pay dividends.
Where can I find CNSP SEC filings?
Official SEC filings for CNS Pharmaceuticals, Inc. (CIK: 0001729427) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CNSP's EPS?
CNS Pharmaceuticals, Inc. has a diluted EPS of $-7.30.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is CNSP's fundamental grade?
Based on our AI fundamental analysis in June 2026, CNS Pharmaceuticals, Inc. has a D grade with 92% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is CNSP stock overvalued or undervalued?
Valuation metrics for CNSP: ROE of -6,982.6% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is CNSP's AI grade for 2026?
Our dual AI analysis gives CNS Pharmaceuticals, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CNSP's free cash flow?
CNS Pharmaceuticals, Inc.'s operating cash flow is $-4.6M, with capital expenditures of $6.2K.
How does CNSP compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -6,982.6% (avg: 15%), current ratio 0.89 (avg: 2).